Alexander Kuo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6753263/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology and Hepatology, 2018, 16, 1811-1819.e4.	4.4	20
2	Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Scientific Reports, 2018, 8, 3199.	3.3	18
3	Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis. European Journal of Gastroenterology and Hepatology, 2018, 30, 1378-1383.	1.6	14
4	Extended Criteria Donors in Liver Transplantation. Clinics in Liver Disease, 2017, 21, 289-301.	2.1	128
5	Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut, 2017, 66, 1844-1852.	12.1	69
6	Interferonâ€free therapy for genotype 1 hepatitis C in liver transplant recipients: Realâ€world experience from the hepatitis C therapeutic registry and research network. Liver Transplantation, 2016, 22, 24-33.	2.4	100
7	Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. Gastroenterology, 2016, 151, 1131-1140.e5.	1.3	199
8	Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. Clinical Infectious Diseases, 2016, 63, 776-783.	5.8	45
9	Intravascular Ultrasound in the Creation of Transhepatic Portosystemic Shunts Reduces Needle Passes, Radiation Dose, and Procedure Time: A Retrospective Study of a Single-Institution Experience. Journal of Vascular and Interventional Radiology, 2016, 27, 1148-1153.	0.5	44
10	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology, 2016, 150, 419-429.	1.3	166
11	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology, 2015, 149, 649-659.	1.3	725
12	Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study. Gastroenterology, 2015, 148, 100-107.e1.	1.3	307
13	Chronic Hepatitis B Infection. Clinics in Liver Disease, 2012, 16, 347-369.	2.1	54
14	ls recurrent hepatitis C worse with living donors?. Current Opinion in Organ Transplantation, 2009, 14, 240-244.	1.6	5
15	Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with benetitis C virus infection. Liver Transplantation, 2008, 14, 1491-1497	2.4	28